SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
StockStory.org on MSN
2 reasons EFX is risky and 1 stock to buy instead
Equifax has gotten torched over the last six months - since October 2025, its stock price has dropped 22.7% to $179.67 per ...
View Equifax Inc. EFX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Barchart on MSN
Earnings preview: What to expect from Equifax's report
With a market cap of $22 billion, Equifax Inc. (EFX)is a global data, analytics, and technology company that provides ...
Mar Vista Investment Partners, LLC, an investment management company, released the “Mar Vista U.S. Quality Select Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded ...
Major release introduces project-based workflows, multi-volume comparison, high-resolution animations, and ASTM E1695 compliance for industrial X-ray and CT professionals worldwide. ROGERS, Minn., ...
(RTTNews) - Akero Therapeutics (AKRO) unveiled new data from its Phase 2b SYMMETRY trial highlighting the potential of efruxifermin - EFX to reverse fibrosis in patients with compensated cirrhosis (F4 ...
The Mandalorian Season 3 has finally aired, and it was a fun and explosive season finale. However, if one person needs an apology from Star Wars fans, it is, The Armorer was labeled a Spy and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results